Contact Info & Biography
Education & Training
Memberships & Awards

Charles N. Ellis, MD

William B. Taylor Professor of Clinical Dermatology, Department of Dermatology

Selected Publications

  1. Ellis CN, Gorsulowsky DC, Hamilton TA, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM, Turcotte JG, Voorhees JJ. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986;256:3110-3116. (Selected for reprinting in 4 international editions.)
  2. Ellis CN, Voorhees JJ. Etretinate therapy. J Am Acad Dermatol. 1987;16:267-291. (Lead CME article)
  3. Weiss JS, Ellis CN, Headington JT, Tincoff T, Hamilton TA, Voorhees JJ. Topical tretinoin improves photoaged skin: A double-blind vehicle-controlled study. JAMA. 1988;259:527-532. (Selected for reprinting in international edition.)
  4. Woodley DT, Zelickson AS, Briggaman RA, Hamilton TA, Weiss JS, Ellis CN, Voorhees JJ. Treatment of photoaged skin with topical tretinoin increases epidermal-dermal anchoring fibrils: A preliminary report. JAMA. 1990;263:3057-3059.
  5. Eisen DE, Ellis, CN, Duell EA, Griffiths CEM, Voorhees JJ. Effect of topical cyclosporine rinse on oral lichen planus: A double-blind analysis. N Engl J Med. 1990;323:290-294.
  6. Ellis CN, Weiss JS, Hamilton TA, Headington JT, Zelickson AS, Voorhees JJ. Sustained improvement with prolonged tretinoin (retinoic acid) for photoaged skin. J Am Acad Dermatol. 1990;23:629-637.
  7. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, Rocher LL, Wheeler S, Hamilton TA, Parish TG, Ellis-Madu M, Duell E, Annesley TM, Cooper KD, Voorhees JJ. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial. N Engl J Med. 1991;324:277-284. (Selected as subject of editorial.)
  8. Rafal ES, Griffiths CEM, Ditre CM, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) treatment for liver spots associated with photodamage. N Engl J Med. 1992;326:368-374.
  9. Bulengo-Ransby SM, Griffiths CEM, Kimbrough-Green CK, Finkel LJ, Hamilton TA, Ellis CN, Voorhees JJ. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443. (Selected as subject of editorial.)
  10. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol. 1995;131:791-795. (Selected as subject of editorial.)
  11. Javier AF, Bata-Csorgo Z, Ellis CN, Kang S, Voorhees JJ, Cooper KD. Rapamycin (sirolimus) inhibits proliferating cell nuclear antigen expression and blocks cell cycle in the G1 phase in human keratinocyte stem cells. J Clin Inv. 1997;99:2094-2099.
  12. Ellis CN, Stevens SR, Blok BK, Taylor RS, Cooper KD. Interferon-gamma therapy reduces blood leukocyte levels in patients with atopic dermatitis: Correlation with clinical improvement. Clin Immunol. 1999;92:49-55.
  13. Ellis CN, Barker JNWN. Psoriasis: A view for the year 2000. Curr Prob Dermatol. 2000;12:45-50.
  14. Ellis CN, Varani J, Fisher GJ, Zeigler ME, Pershadsingh HA, Benson SC, Chi Y, Kurtz TW. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: Ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136:609-616.
  15. Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am J Clin Dermatol. 2001;2:33-39.
  16. Ellis CN, Leyden J, Katz HI, Goldfarb MT, Hickman J, Jones TM, Tschen E. Therapeutic studies with a new combination benzoyl peroxide/clindamycin topical gel in acne vulgaris. Cutis. 2001;67(2S):13-20.
  17. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory-effector T lymphocytes. N Engl J Med. 2001;345:248-255. (Selected as subject of editorial) (Letters and responses, 2001;345:1853-1855)
  18. Nyirady J, Bergfeld W, Ellis C, et al. Tretinoin cream 0.02% for the treatment of photodamaged facial skin: A review of 2 double-blind clinical studies. Cutis. 2001;68:135-142.
  19. Ellis CN, Krach KJ. Uses and complications of isotretinoin therapy. J Am Acad Dermatol. 2001;45:S150-157.
  20. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis with a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate. J Am Acad Dermatol. 2002;46:242-250.
  21. Ellis CN, Reiter KL, Wheeler JRC, Fendrick AM. Economic analysis in dermatology. J Am Acad Dermatol. 2002;46:271-283.
  22. Ellis CN, Drake LA, Prendergast MM, et al. Cost of eczema and atopic dermatitis in the United States. J Am Acad Dermatol. 2002;46:361-370.
  23. Ellis CN, Brown MF, Voorhees JJ. Sulfasalazine for alopecia areata. J Am Acad Dermatol. 2002;46:541-544.
  24. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2002;47:821-833.
  25. Ellis CN, Mordin MM, Adler EY. Effects of alefacept on health-related quality of life in patients with psoriasis; Results from a randomized, placebo-controlled phase II trial. Am J Clin Dermatol. 2003;4:131-139.
  26. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol. 2003;42:224-230.
  27. Ellis CN, Drake LA, Prendergast MM, et al. Cost-effectiveness analysis of tacrolimus ointment versus high-potency topical corticosteroids in adults with moderate to severe atopic dermatitis. J Am Acad Dermatol. 2003;48:553-563.
  28. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. British J Dermatol. 2003;148:784-788.
  29. Ellis C, Luger T, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Clinical update and current treatment strategies. British J Dermatol. 2003;148 (Suppl 63):3-10. (Chairman's introduction and overview, pp. 1-3).
  30. Ellis CN, Drake LA, Prendergast MM, et al. Validation of expert opinion in identifying comorbidities associated with atopic dermatitis/eczema. Pharmacoeconomics. 2003;21:875-883.
  31. Bhagavathula N, Nerusu KC, Lal A, Ellis CN, Chittiboyina A, Avery MA, Ho C I, Benson SC, Pershadsingh HA, Kurtz TW, Varani J. Rosiglitazone inhibits proliferation, motility, and matrix metalloproteinase production in keratinocytes. J Invest Dermatol. 2004;122:130-139.
  32. Griffiths, CEM, Dubertret L, Ellis CN et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. British J Dermatol. 2004;150(s67):11-23.
  33. Venkatraman MS, Chittiboyina A, Meingassner J, Ho CI, Varani J, Ellis CN, Avery MA, Pershadsingh HA, Kurtz TW, Benson SC. alpha-Lipoic acid-based PPARgamma agonists for treating inflammatory skin diseases. Arch Dermatol Res. 2004;296:97-104.
  34. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol. 2004;51:563-569.
  35. Ellis CN, Pillitteri JL, Kyle TK, Ertischek MD, Burton SL, Shiffman S. Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone. J Am Acad Dermatol. 2005;53:41-51. [Correspondence: J Am Acad Dermatol. 2006;54:182-3.]
  36. Krueger G, Ellis CN. Psoriasis - Recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94-100.
  37. Gisondi P, Ellis CN, Girolomoni G. Pimecrolimus in dermatology: atopic dermatitis and beyond. Int J Clin Pract. 2005;59:969-974.
  38. Bieber T, Cork M, Ellis CN, et al. Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology. 2005;211:77-78.
  39. Gupta MA, Gupta AK, Ellis CN, Koblenzer CS. Psychiatric evaluation of the dermatology patient. Dermatol Clin. 2005;23:591-599.
  40. Ellis CN, Solomon AR. Histologic evaluation of melanomas. Arch Dermatol. 2005;141:1466.
  41. Pershadsingh HA, Benson SC, Ellis CN. Improvement in psoriasis with rosiglitazone in a diabetic and a nondiabetic patient. Skinmed. 2005;4:386-390.
  42. Bhagavathula N, Nerusu KC, Reddy M, Ellis CN, Chittiboyina A, Avery M, Pershadsingh HA, Kurtz TW, Varani J. BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application. J Pharmacol Exp Ther. 2005;315:996-1004.
  43. Ellis CN, Kahler KH, Grueger J, Chang J. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. Am J Clin Dermatol. 2006;7:133-139.
  44. Kia KF, Tavakkoli A, Ellis CN. Clinical e-mail in an academic dermatology setting. J Am Acad Dermatol. 2006;54:1019-1024.
  45. Griffiths CEM, et al (Guest Ed.: Ellis CN). Update on the use of ciclosporin in immune-mediated dermatoses. Br J Dermatol. 2006;155 (Suppl. 2):1-16.
  46. Kia, KF, Gielczyk RA, Ellis CN. Academia is the life for me, I'm sure. Arch Dermatol. 2006;142:911-913. [Research study and editorial on residents' predicted and actual career choices.]
  47. Varani J, Bhagavathula N, Ellis CN, Pershadsingh HA. Thiazolidinediones: Potential as therapeutics for psoriasis and perhaps other hyperproliferative skin diseases. Expert Opin Investig Drugs. 2006;1453-1468.
  48. Callen J, Chamlin S, Eichenfield LF, Ellis C, et al. A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007;156:203-221.
  49. Eichenfield L, Ellis CN, Fivenson D, Herbert AA, Dromgoole S, Piacquadio D. Evaluation of adrenal suppression of a lipid enhanced, topical emollient cream for-mulation of hydrocortisone butyrate 0.1% in treating children with atopic dermatitis. Pediatr Dermatol. 2007;24:81-84.
  50. Ellis CN, Barker JN, Haig AE, Parker CA, Daly S, Jayawardene DA. Placebo response in two long term randomized psoriasis studies that were negative for rosiglitazone. Am J Clin Dermatol. 2007;8:93-102.
  51. Kia KF, Nair R, Ike RW, Hiremagalore R, Elder JT, Ellis CN. Prevalence of antigliadin antibodies in patients with psoriasis is not elevated compared with controls. Am J Clin Dermatol. 2007;8:301-305.